SCHEMBL6764327

SCHEMBL6764327

Nc1ccc(C(=O)NCCCN2CCCC2)cn1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KIT P10721 1/20 0.57
MAPT P10636 2/20 0.56
RECQL P46063 1/20 0.56
LMNA P02545 2/20 0.52
ALDH1A1 P00352 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
GAA P10253 1/20 0.52
MAPK1 P28482 1/20 0.52
HTT P42858 1/20 0.52
EPHX2 P34913 2/20 0.52
L3MBTL3 Q96JM7 2/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
NAMPT P43490 1/20 0.52
PHF13 Q86YI8 1/20 0.51
SMYD2 Q9NRG4 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13450275 0.91 KIT (0.64) KITALDH1A1EPHX2L3MBTL1NPSR1
SCHEMBL13450228 0.90 SMN1; SMN2 (0.56) KITMAPTLMNAALDH1A1SMN1; SMN2
SCHEMBL2236934 0.89 LMNA (0.55) KITMAPTLMNAALDH1A1SMN1; SMN2
SCHEMBL13403410 0.89 SMN1; SMN2 (0.65) ALDH1A1SMN1; SMN2NAMPTCYP2D6CYP2C9
SCHEMBL13403409 0.81 KDM4E (0.55) KITALDH1A1GAAEPHX2L3MBTL1
SCHEMBL22874354 0.79 HDAC1 (0.51) MAPTRECQLEPHX2NAMPT
SCHEMBL9199198 0.79 LMNA (0.67) MAPTRECQLLMNAALDH1A1SMN1; SMN2
SCHEMBL10730956 0.78 EPHX2 (0.59) SMN1; SMN2HTTEPHX2L3MBTL1
SCHEMBL2955185 0.78 MAPT (0.60) MAPTRECQLLMNAALDH1A1SMN1; SMN2
SCHEMBL14430781 0.77 HPGDS (0.54) MAPTRECQLEPHX2NAMPTSMYD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040063725-A1 Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use LABORATORIES FOURNIER S.A. (FR) 2004-04-01 US disclosed
EP-1351928-A2 NOVEL N(PHENYLSULPHONYL)GLYCINE DERIVATIVES AND THEIR THERAPEUTIC USE LABORATOIRES FOURNIER S.A. (FR) 2003-10-15 EP disclosed
WO-2002053516-A2 N(PHENYLSULPHONYL)GLYCINE DERIVATIVES AND THEIR THERAPEUTIC USE LABORATOIRES FOURNIER SA (FR) 2002-07-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063725-A1 Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use GLS, GLS2, GLRB KIT 579/4885MAPT 1262/4885RECQL 4156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.